Search for content, post, videos

Xbrane’s Spherotide granted market authorization in Iran


Xbrane Biopharma’s partner Pooyesh Darou has been granted market authorization for sales and marketing of Spherotide 1 month formulation in Iran under the local brand name Microrelin.

“This is a major milestone for Xbrane as it is the first Market Authorization granted for Spherotide to a local sales and marketing partner. This demonstrates the quality and performance of the product. We are confident that Spherotide will contribute positively to the Iranian healthcare system with a more cost-efficient treatment option than currently available for targeted indications.” says Martin Åmark, Xbranes CEO.

Spherotide is a generic long acting formulation with the active substance triptorelin and is used in the treatment of prostate cancer, endometriosis, uterine fibroids, precocious puberty and breast cancer. The drug is based on encapsulation of the active ingredient in biodegradable microspheres that degrade in the body after injection and create a long acting effect. The originator product is estimated to generate annual sales of approximately $ 500 million globally and $ 30 million in the Middle East.